세계의 대사이상 관련 지방간염(MASH) 치료 시장 보고서(2025년)

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025

US $ 4,490 ￦ 6,242,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,023,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,803,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

대사장애 관련 지방간염(MASH) 치료제 시장 규모는 향후 수년간 비약적인 성장이 전망됩니다. 2029년에는 연평균 성장률(CAGR) 29.8%로 73억 8,000만 달러로 성장합니다. 예측 기간 중 예상되는 성장의 원동력은 비만 및 비만 관련 질환의 비율 증가, 조기 개입, 상환 제도 개선, 보험 적용 범위 확대, 간 질환에 대한 인식 증가 등입니다. 이 기간을 형성할 것으로 예상되는 주요 동향으로는 기술 발전, 파이프라인의 새로운 치료법 개발, 전략적 제휴 및 공동 연구, 맞춤형 의료, 정밀 치료, 임상시험 및 연구 투자 증가 등이 있습니다.

비만의 확산이 향후 대사장애 관련 지방간염(MASH) 치료제 시장의 성장을 촉진할 것으로 예측됩니다. 비만은 체지방이 과도하게 축적되어 건강에 해를 끼칠 수 있는 상태를 말하며, 일반적으로 체질량지수(BMI) 30 이상으로 정의됩니다. 전 세계에서 비만 증가는 주로 좌식 생활방식, 식습관 장애, 대사 위험 등의 요인에 기인합니다. 비만에서 MASH 치료는 생활습관 개선과 표적 치료를 통해 인슐린 저항성과 싸우고, 간 지방을 감소시키고, 대사 건강을 향상시키는 것을 목표로 합니다. 예를 들어 2023년 3월에 발표된 스위스에 본부를 둔 세계 심장 재단의 보고서에 따르면 전 세계 성인과 어린이의 약 23억 명이 비만 또는 과체중이며, 이 수치는 진행 중인 비만 추세를 반영하여 2025년까지 27억 명으로 증가할 것으로 예측됩니다. 결과적으로 비만율 증가는 MASH 치료 시장의 성장을 가속하고 있습니다.

대사장애 관련 지방간염(MASH) 치료제 시장의 주요 업체들은 간섬유증 치료제를 포함한 혁신적인 제품 개발에 주력하고 있습니다. 이러한 치료는 생활습관 개선, 항바이러스제, 새로운 항섬유화 요법을 중심으로 간 손상의 근본 원인을 해결하는 것을 목표로 하고 있습니다. 목표는 섬유화의 진행을 예방하고, 섬유화 진행을 역전시키고, 간 기능을 향상시키는 것입니다. 예를 들어 2024년 3월 미국 바이오 제약사 마드리갈 파마슈티컬스(Madrigal Pharmaceuticals)는 레스디훌라(레스메티롬)의 FDA 승인을 받았습니다. 중등도에서 중증의 간섬유화를 동반한 MASH에 대한 최초의 치료제입니다. 1일 1정 경구제인 레스디플라는 임상 3상 시험에서 섬유증을 악화시키지 않고 MASH를 해소하고 간섬유증을 개선하는 효능을 입증했습니다. 이 획기적인 신약은 간 생검을 대체할 수 있는 비침습적 치료법을 제공함으로써 지방간 질환 관리에 대한 환자 접근성과 치료 결과를 크게 개선할 수 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 대사이상 관련 지방간염(MASH) 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 용도 산업의 분석
• 세계의 대사이상 관련 지방간염(MASH) 치료 시장 : 성장률 분석
• 세계의 대사이상 관련 지방간염(MASH) 치료 시장 실적 : 규모와 성장, 2019-2024
• 세계의 대사이상 관련 지방간염(MASH) 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 대사이상 관련 지방간염(MASH) 치료 TAM(Total Addressable Market)

제6장 시장 세분화

• 세계의 대사이상 관련 지방간염(MASH) 치료 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 약물별
• 테라피별
• 세계의 대사이상 관련 지방간염(MASH) 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 전문 클리닉
• 홈케어
• 기타 최종사용자
• 세계의 대사이상 관련 지방간염(MASH) 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 온라인 약국
• 소매 약국
• 세계의 대사이상 관련 지방간염(MASH) 치료 시장, 약제별의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 항섬유화제
• 항당뇨병약
• 지질 저하제
• 비타민 E
• OCA(Obeticholic Acid)
• GLP-1 작용제
• 기타 약제(항염증약)
• 세계의 대사이상 관련 지방간염(MASH) 치료 시장, 치료법별의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 약물 요법
• 라이프스타일의 변경(식생활의 변경, 운동)
• 비만 수술
• 간 이식

제7장 지역별·국가별 분석

• 세계의 대사이상 관련 지방간염(MASH) 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 대사이상 관련 지방간염(MASH) 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 대사이상 관련 지방간염(MASH) 치료 시장 : 경쟁 구도
• 대사이상 관련 지방간염(MASH) 치료 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 대기업과 혁신적 기업

• Novartis AG
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Apollo Health and Lifestyle Limited
• Jenny Craig
• Celerion
• Nutrisystem
• Madrigal Pharmaceuticals
• Anoos Clinic
• 31.13. Biosynth
• 31.14. DiogenX
• 31.15. Galectin Therapeutics Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 대사이상 관련 지방간염(MASH) 치료 시장 2029 : 새로운 기회를 제공하는 국가
• 대사이상 관련 지방간염(MASH) 치료 시장 2029 : 새로운 기회를 제공하는 부문
• 대사이상 관련 지방간염(MASH) 치료 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁의 전략

제36장 부록

KSA

영문 목차

영문목차

Treatment for metabolic dysfunction-associated steatohepatitis (MASH) involves both medical and lifestyle approaches that target the inflammation and liver damage caused by fat buildup in the liver, which is linked to metabolic issues such as obesity, diabetes, and insulin resistance. The goal is to improve liver function and metabolic health outcomes.

The primary treatments for MASH include medications and therapies. Drug treatments involve the use of pharmaceutical agents to reduce liver inflammation, fibrosis, and fat accumulation, aiming to enhance liver function and halt disease progression. These treatments are provided to patients through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and specialty clinics, and can be used in settings such as hospitals, homecare, and others.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report is one of a series of new reports from The Business Research Company that provides metabolic dysfunction-associated steatohepatitis (MASH) treatment market statistics, including metabolic dysfunction-associated steatohepatitis (MASH) treatment industry global market size, regional shares, competitors with metabolic dysfunction-associated steatohepatitis (MASH) treatment market share, detailed metabolic dysfunction-associated steatohepatitis (MASH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic dysfunction-associated steatohepatitis (MASH) treatment industry. This metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size has grown exponentially in recent years. It will grow from $2.00 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 30.0%. The growth observed in the historical period can be linked to the increasing prevalence of non-alcoholic steatohepatitis, modern dietary trends that include high consumption of processed foods, sedentary lifestyles, and the rising occurrence of metabolic conditions.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size is expected to see exponential growth in the next few years. It will grow to $7.38 billion in 2029 at a compound annual growth rate (CAGR) of 29.8%. The anticipated growth during the forecast period is driven by the rising rates of obesity and obesity-related conditions, early interventions, improved reimbursement mechanisms, expanded insurance coverage, and heightened awareness of liver diseases. Key trends expected to shape this period include advancements in technology, the development of new treatments in the pipeline, strategic partnerships and collaborations, personalized medicine, precision therapeutics, and increased investment in clinical trials and research.

The growing prevalence of obesity is expected to drive the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in the future. Obesity is a condition marked by excessive body fat accumulation, which can harm overall health and is usually defined by a body mass index (BMI) of 30 or higher. The global rise in obesity is primarily attributed to factors such as sedentary lifestyles, poor dietary habits, and metabolic risks. MASH treatment in obesity aims to combat insulin resistance, reduce liver fat, and enhance metabolic health through both lifestyle modifications and targeted treatments. For example, a report from the World Heart Foundation, a Switzerland-based global cardiovascular organization, published in March 2023, highlighted that around 2.3 billion adults and children worldwide are obese or overweight, and this figure is expected to increase to 2.7 billion by 2025, reflecting the ongoing obesity trend. Consequently, the rise in obesity rates is propelling the growth of the MASH treatment market.

Major companies in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are focusing on the development of innovative products, including solutions for liver fibrosis. These treatments aim to address the root causes of liver damage, with a focus on lifestyle changes, antiviral medications, and emerging antifibrotic therapies. The goal is to prevent the progression of fibrosis, potentially reversing it, and enhancing liver function. For example, in March 2024, Madrigal Pharmaceuticals, a US-based biopharmaceutical company, received FDA approval for Rezdiffra (resmetirom). This is the first-ever treatment for MASH with moderate to severe liver fibrosis. Rezdiffra, a daily oral tablet, showed effectiveness in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This breakthrough provides a non-invasive alternative to liver biopsies, significantly improving patient access and outcomes in managing fatty liver disease.

In January 2024, Suzhou Ribo Life Science Co., Ltd., a clinical-stage company based in China, and Ribocure Pharmaceuticals AB (Ribo), a clinical-stage biotechnology company from Sweden, announced a $2 billion collaboration with Boehringer Ingelheim. This partnership aims to develop innovative treatments for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will combine Ribo's RNAi therapeutic platform with Boehringer Ingelheim's expertise in cardiovascular, renal, and metabolic diseases. The goal is to address the critical need for effective therapies that can halt the progression of NASH and restore liver function. Boehringer Ingelheim, a pharmaceutical company based in Germany, is actively working on treatments for MASH.

Major players in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, and Hepion Pharmaceuticals.

North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metabolic dysfunction-associated steatohepatitis (MASH) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market consists of revenues earned by entities by providing services such as clinical care services, nutritional counseling, pharmacotherapy management, patient education, and support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic dysfunction-associated steatohepatitis (MASH) treatment market also includes sales of antioxidants, antidiabetic drugs, and liver protective supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metabolic dysfunction-associated steatohepatitis (mash) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metabolic dysfunction-associated steatohepatitis (mash) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolic dysfunction-associated steatohepatitis (mash) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: By Drug; By Therapy
• 2) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-User
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Drug: Antifibrotic Agents; Antidiabetic Drugs; Lipid-Lowering Agents; Vitamin E; Obeticholic Acid (OCA); GLP-1 Agonists; Other Drugs (Anti-Inflammatory Agents)
• 2) By Therapy: Pharmacotherapy; Lifestyle Modifications (Dietary Changes, Exercise); Bariatric Surgery; Liver Transplantation
• Companies Mentioned:Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Sanofi SA; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Characteristics

3. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Trends And Strategies

4. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Rate Analysis
• 5.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Total Addressable Market (TAM)

6. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Segmentation

• 6.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• By Drug
• By Therapy
• 6.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-User
• 6.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• 6.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifibrotic Agents
• Antidiabetic Drugs
• Lipid-Lowering Agents
• Vitamin E
• Obeticholic Acid (OCA)
• GLP-1 Agonists
• Other Drugs (Anti-Inflammatory Agents)
• 6.5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacotherapy
• Lifestyle Modifications (Dietary Changes, Exercise)
• Bariatric Surgery
• Liver Transplantation

7. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Regional And Country Analysis

• 7.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 8.1. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 9.1. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 9.2. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 10.1. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 11.1. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 11.2. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 12.1. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 13.1. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 14.1. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 14.2. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 15.1. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 15.2. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 16.1. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 17.1. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 18.1. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 19.1. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 20.1. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 21.1. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 21.2. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 22.1. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 23.1. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 23.2. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 24.1. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 24.2. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 25.1. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 25.2. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 26.1. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 26.2. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 27.1. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 28.1. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 28.2. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 29.1. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 29.2. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape
• 30.2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Eli Lilly and Company
• 31.3. Gilead Sciences Inc.
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Novo Nordisk A/S
• 31.6. Apollo Health and Lifestyle Limited
• 31.7. Jenny Craig
• 31.8. Celerion
• 31.9. Nutrisystem
• 31.10. Madrigal Pharmaceuticals
• 31.11. Anoos Clinic
  • 31.12. 89 Bio
• 31.13. Biosynth
• 31.14. DiogenX
• 31.15. Galectin Therapeutics Inc.

32. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

34. Recent Developments In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

35. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료